IDEXX Laboratories (NASDAQ:IDXX) Reaches New 1-Year Low Following Insider Selling

IDEXX Laboratories, Inc. (NASDAQ:IDXX)’s share price reached a new 52-week low during trading on Wednesday following insider selling activity. The stock traded as low as $515.86 and last traded at $519.3270, with a volume of 24987 shares. The stock had previously closed at $520.21.

Specifically, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IDXX. UBS Group lifted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup raised their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays cut their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Price Performance

The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a market capitalization of $39.90 billion, a P/E ratio of 35.62, a price-to-earnings-growth ratio of 2.75 and a beta of 1.54. The firm has a 50-day moving average price of $556.66 and a 200 day moving average price of $566.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.IDEXX Laboratories’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors have recently made changes to their positions in IDXX. SHP Wealth Management bought a new stake in IDEXX Laboratories in the fourth quarter worth $26,000. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth about $26,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $25,000. Elevation Wealth Partners LLC lifted its stake in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares during the last quarter. Finally, Wormser Freres Gestion lifted its stake in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.